VIRONEXX
Vironexx develops first-in-class monoclonal antibodies with the ability to prevent and cure hepatitis C infection, which progressively causes liver damage. They will target patients for whom there is currently no treatment option: transplant patients and multidrug-resistant patients with available therapies. Vironexx will deliver a preclinical package discarded to the pharmaceutical industry.
VIRONEXX
Industry:
Biotechnology
Founded:
2012-10-01
Address:
Strasbourg, Alsace, France
Country:
France
Status:
Active
Email Addresses:
[email protected]
Similar Organizations
Coridon
Coridon develops DNA therapies for the prevention and treatment of viral infections, and therapeutic vaccines for the treatment of cancer.
Karveel Pharmaceuticals
Karveel Pharmaceuticals develops antibiotics for the treatment of serious drug-resistant infections.
Oncodesign
Oncodesign develops anticancer therapies for the treatment of patients with cancer.
OY LX Therapies
OY LX Therapies is focused on developing gene-mediated therapies for the prevention and treatment of diseases of lymphatic vasculature.
Polygon Therapeutics
Polygon Therapeutics develops innovative biomedicines for the treatment of cardiovascular diseases.
RQ Bio
RQ Bio develops medicine based on potent broad-spectrum mAbs to provide immunity to viral infections.
SynCell Biotechnology
SynCell Biotechnology develops nano-therapeutics for the prevention and treatment of skin infections.
Ventaleon
Ventaleon is developing inhaled treatments against viral infections.
WntResearch
WntResearch develops anti-metastatic therapies for the treatment of cancer patients.
Founder
More informations about "Vironexx"
Vironexis Biotherapeutics - Crunchbase Company Profile & Funding
Vironexis will implement the cutting-edge technique of AAV-delivered T-cell immunotherapy. A platform for creating off-the-shelf, single-dose T-cell immuno-gene therapies that redirect T …See details»
Vironexis Biotherapeutics
Our AAV-delivered T-cell Immunotherapy builds on the power of T-cell immunotherapy while leveraging AAV delivery to overcome the shortcomings and challenges of existing approaches. We aim to revolutionize the …See details»
Vironexx - Crunchbase Company Profile & Funding
Vironexx develops innovative therapies for prevention and treatment of viral infections. There is no recent news or activity for this profile. Vironexx develops first-in-class monoclonal …See details»
Vironexis Biotherapeutics - Funding, Financials, Valuation & Investors
Vironexis Biotherapeutics is funded by 4 investors. Future Ventures and Drive Capital are the most recent investors. Which investors participated in the most funding rounds? Vironexis has …See details»
Vironexis Biotherapeutics Launches with FDA Clearance of IND ...
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Vironexis Biotherapeutics, focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell …See details»
Gene therapy startup emerges with green light for first-of-its-kind ...
Sep 12, 2024 · Vironexis Biotherapeutics emerged from stealth with plans to start what it claims will be the first-ever clinical trial testing a cancer immunotherapy delivered with the help of an …See details»
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 · Vironexis currently touts at least 10 preclinical pipeline candidates—including one cancer vaccine—that mostly take aim at blood-based cancers and solid tumor metastasis …See details»
Vironexx SAS - Drug pipelines, Patents, Clinical trials - Synapse
Explore Vironexx SAS with its drug pipeline, therapeutic area, technology platform, , Drug:VNX-001.See details»
Research programme: hepatitis C therapeutics - Vironexx
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. Vironexx was developing first-in-class monoclonal antibodies for the …See details»
Vironexis AAV vectors: oncology's next big thing? - labiotech.eu
Sep 16, 2024 · But unlike other immuno-oncology companies, Vironexis’s approach comes with a twist: it uses adeno-associated viruses (AAV) vectors to deliver gene therapy against cancer. …See details»
VNX-001 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 9, 2024 · VNX-001: a CLDN1 inhibitors Drug, Initially developed by Vironexx SAS, Now, its global highest R&D status is Pending, Mechanism: CLDN1 inhibitors (Claudin 1 inhibitors), …See details»
BioCentury - Vironexis’ AAV tech to express protein therapeutics; …
Jul 16, 2022 · A group led by Timothy Cripe at Nationwide Children’s Hospital designed a recombinant adeno-associated virus (AAV) vector to express bispecific T cell engager Blincyto …See details»
Cancer gene therapy startup Vironexis emerges from stealth with …
Sep 12, 2024 · A new startup attempting to develop AAV gene therapies to treat cancer emerged from stealth Thursday morning with $26 million in seed funding — and a plan to quickly get into ...See details»
Vivonex® Resources - Nestlé Medical Hub
Discover Nestlé Health Science. See how Nestlé Health Science is advancing nutrition innovation and empowering healthcare professionals as a global leader in nutritional science.See details»
VIVONEX® RTF Complete Elemental Nutrition - Nestlé Medical Hub
Ready-to-feed complete elemental nutrition with 100% free amino acids and 10% fat for those with severely impaired gastrointestinal function. This product is intended for use under medical …See details»
Vivonex T.E.N. - Features and Ingredients | Nestlé Health Science
Vivonex ® T·E·N is a powdered, nutritionally complete, elemental formula with 100% free amino acids providing 1.0 Cal/ml with 15% protein equivalent and 3% calories from fat for severely …See details»
VIVONEX® Plus Elemental Powder | Nestlé Medical Hub
Vivonex® PLUS should be utilized only under medical supervision. Elemental Powder. This elemental formula contains 100% free amino acids and a low fat content for those with severe …See details»
Vironexis Biotherapeutics Launches with FDA Clearance of IND ...
Sep 12, 2024 · SAN DIEGO, CA, USA I September 12, 2024 I Vironexis Biotherapeutics, focused on transforming the future of cancer treatment by pioneering AAV-delivered T-cell …See details»
Vivonex Plus - Features and Ingredients | Nestlé Health Science
Vivonex® Plus is a powdered, nutritionally complete, elemental formula with 100% free amino acids. Discover more here.See details»
Vivonex® RTF Unflavored - Nestlé Medical Hub
Notes & Disclaimers for Key Benefits (Healthcare Professionals) *Vivonex® RTF is formulated to contain low quantities of fat which, under some circumstances, may be insufficient to meet the …See details»